3.09
-3.74%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Molecular Partners AG ADR
Its shares trade under the ticker MOLN. It has been listed since 16 June 2021. In the fiscal year to 31 December 2024, it reported revenue of $6.1m and a net loss of $66.8m. At that date it held total assets of $196.0m and shareholders' equity of $175.1m.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 2021
- Employees
- 130
- Website
- molecularpartners.com ↗
- Head office
- WAGISTRASSE 14, Schlieren-Zurich, V8, 8952
- Incorporated in
- V8
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Molecular Partners AG's MP0317 is in Phase 2 for advanced solid tumors in Switzerland.
- MP053 is a novel tetra-specific T cell-engaging DARPin in Phase 1 for acute myeloid leukemia.
- MP0712 targets DLL3 for SCLC and neuroendocrine tumors in Phase 1 clinical trials.
Weaknesses
- MP0726 is a Radio-DARPin Therapy candidate for ovarian cancer in early development.
- MP0621 is a Switch-DARPin candidate for hematopoietic stem cell transplantation in early stages.
- The company's collaboration with Orano Med SAS is for novel Radio-DARPin therapeutics development.
Opportunities
- MP0712's Phase 1 trial for SCLC and neuroendocrine tumors shows potential growth.
- MP053's Phase 1 trial for acute myeloid leukemia offers new treatment avenues.
- The Radio-DARPin Therapy platform enables targeted delivery of radioactive payloads to tumors.
Threats
- MP0317's Phase 2 trial for advanced solid tumors faces competition in oncology.
- MP053's Phase 1 trial for acute myeloid leukemia requires significant funding.
- MP0712's Phase 1 trial for SCLC and neuroendocrine tumors has regulatory hurdles.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.